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[Role-Playing Fred H. Gage
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San Diego, CA]
Summary
Central nervous system (CNS) cells have
historically been characterized by low proliferation
and neural differentiation, with an inability to repair
or replace themselves following damage or
degeneration.  Widespread scientific efforts have
therefore been made to outsmart the restrictive
mechanism of the CNS and to address the
devastation caused by this shortcoming.  Although
stem cells were initially thought to be tissue-
specific in their ability to differentiate and
proliferate, they have demonstrated the capacity to
achieve functional neuronal identity when provided
access to a permissive neural environment.
Aguayo et al. (1980) proposed that the failure of
CNS neurons to regenerate is not an intrinsic deficit
of the neuron, but rather a characteristic feature of
the environment that either does not support, or
prevents regeneration1. My lab’s success in
isolating stem cells from CNS tissues and inducing
them to adopt a neuronal fate, both in vitro and in
v i v o  upon transplantation, supports this
suggestion. Therefore, others and we have made
significant progress in identifying diverse sources
of stem cells, determining elements required for the
generation of functional CNS neurons, and
exploring the potential of these cells for therapeutic
neuroregenerative strategies through stem cell and
gene therapy.
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The Stem Cell Frontier
Stem cells (SCs) can be loosely defined as cells having
some capacity for self-renewal, which can generate or
give rise to specialized cell types other than
themselves.  In vertebrates, they have traditionally been
divided into two groups: ES (embryonic stem) cells or
pluripotent SCs, capable of becoming any cell type in
the body, and tissue-specific stem cells or mutipotent
stem cells, which arise from ES cells and generate the
cell types comprising a particular tissue 1.
It had long been believed that tissue-specific
stem cells could only differentiate into cells of the tissue
of origin.  However, recent studies suggested otherwise
by demonstrating the ability of bone marrow (BM) stem
cells to contribute to and acquire properties of many
tissue cell types, including midbrain neuronal cells2.
Profound devastation is caused by the
inability of central nervous system neurons to
                                                 
1This paper was written for BIO324 Molecular Neuroscience. In this
assignment, Tammy Hibler role-played a noted neuroscientist, Fred Gage,
and wrote a state–of-the-art review article on Dr. Gage’s research field, as
is she were Dr. Gage herself. She then presented a PowerPoint seminar
as Dr. Gage in an annual public student research conference
“NeuroFrontiers” held at Lake Forest College.
regenerate correct axonal and dendritic connections
following injury or degeneration. Therefore, scientists
like myself have been inspired to further investigate the
sources and plasticity of stem cells for potential
application in methods of regeneration or replacement
of damaged CNS cells.
Efforts have since determined that
neurogenesis actually continues throughout adulthood
in discreet regions of the central nervous system, due
to the presence of stem cells with proliferative abilities
in these regions.  These cells can be directed toward
specific neuronal fates both in vivo and in vitro upon
exposure to a permissive neural environment.
Insight into stem cell plasticity, along with the
knowledge gained thus far of cues required to initiate
neuronal differentiation of stem cells, has led us to
realize the potential for regeneration of damaged
neurons in the CNS.  Thus, the ability to initiate
neurogenesis in damaged CNS tissue through either
stem cell or gene therapy could provide possible
treatments for severe neurodegenerative diseases.
Mission 1: The Search for Stem Cells
The Adult Forebrain: It’s Alive!
In order for stem cell therapy to exist as a realistic
possibility for the replacement of degenerated neurons,
usable and attainable sources, or “pools,” of stem cells
must be identified in the CNS.  The hippocampus is the
most thoroughly studied source of CNS stem cells, and
is also one of the only areas where new nerve cells are
generated in the adult brain.  Hence, it makes sense to
begin our discussion of stem cells and their potential
with this structure.
To investigate the prospective utility of
hippocampal neurogenesis in the adult brain, it is
important to determine factors allowing for the
enhanced generation of these cells and their potential
functionality due to such factors.  We therefore
conducted experiments manipulating the living
environment of mice.  In a 1997 study, we found that
significantly more new neurons arise in the
hippocampus of mice living in an enriched environment,
consisting of a large cage with tunnels, wheels, and
toys, when compared to littermates housed in standard
cages3.
A subsequent study in 1999 determined that
running in particular contributes significantly to
neurogenesis4.  This study also demonstrated a
correlation between enhanced neurogeneration and
behavioral functionality in that spatial learning and long-
term potentiation improved in mice stimulated through
voluntary activity, indicating that certain factors can
contribute positively to the behavioral function of the
mouse.
To address whether the enhanced
neurogeneration precedes the increased functional
ability of the cells, we investigated the functionality of
the individual neurons in a 2002 study, using cues
including expression of neuronal markers (NeuN),
e v i d e n c e  f o r  s y n a p t i c  t r a n s m i s s i o n
(calbindin/synaptophysin expression), existence of
spines in the dendrites and synaptic terminals, and the
presence of electrophysiological properties (membrane
potential, currents, firing rate)5.  We found that these
cells do have neuronal morphology and can display
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passive membrane properties, action potentials, and
functional synaptic inputs similar to those found in
mature dentate granule cells.
The degree of pluripotency of these
hippocampal progenitor cells had already been
demonstrated by our lab in 1996, by grafting adult
hippocampal neurons (AHPs) into the rostral migratory
pathway and observing their ability to both migrate into
the olfactory bulb and differentiate into tyrosine-
hydroxylase positive neurons characteristic of this
region6.  The functionality of newly generated neurons
in the hippocampus, and the degree of pluripotency of
the cells, both demonstrated by our lab, support the
application of AHP populations as endogeneous
progenitors.
Is there more life out there?
To extend the valuable and exciting knowledge already
gained concerning stem cell potential, we must identify
additional sources of stem cells to determine what cell
types may arise from them, and if they too have the
ability to differentiate to a neuronal fate.
We therefore examined the proliferation,
distribution, and phenotypic fate of dividing cells in the
rat spinal cord in a 2000 study7.  These proliferating
CNS cells were able to divide in situ, rather than
generating in and migrating from the ventricles in the
brain already known to produce such cells.  These cells
demonstrated the ability to differentiate into mature
oligodendrocytes and astrocytes, which is not surprising
considering that periodic renewal of glial cells is
required for continued to support and nourishment of
these CNS neurons.
These results, however, proposed a higher
level of cellular plasticity for the intact adult spinal cord
than that previously observed, suggesting that the adult
neuronal character of the spinal chord should be re-
evaluated for potential neuronal generation.  It was
possible that perhaps these cells do not maintain their
intrinsic restrictions when provided with differing cues.
To investigate this idea, my lab and I used the
knowledge we had gained from a 1999 study in which
we demonstrated the ability of Fibroblast Growth
Factor-2 (FGF-2) to induce precursors, native to
regions of the adult brain that generate only glia, to
adopt a neuronal identity8.  Aside from confirming that
neuron competent precursors exist naturally in widely
divergent tissues of the adult brain, it also highlighted
the applicability of this growth factor for the signaling of
adult spinal progenitors.
Our subsequent application of FGF-2 in
2000, to the spinal cord-derived progenitors, did lead to
the generation in vitro of neurons as well as the
astrocytes and oligodendrocytes seen previously9.  Our
ability to employ FGF-2 to induce neuronal fate inspired
us to experimentally manipulate this newfound adult
spinal progenitor population in vivo.  We demonstrated,
in this same study, that transplantation of these clonal
cells back into the adult rat spinal cord results in their
differentiation into glial cells only, which was the in vitro
fate originally observed for this cell population.
However, when transplanted into the adult dentate
gyrus (hippocampus), these cells integrated into the
granular cell layer and differentiated into neural cells
characteristic of this region9.  This study therefore
demonstrates the importance of environmental cues in
directing cellular fates.
Are these Sources Realistic and Ethical?
In considering stem cell therapy and its practicality, we
must not only address where applicable sources of
stem cells exist, but also whether these sources are
exploitable.  We cannot simply obtain mass amounts of
stem cells from healthy people to treat those with
neurological ailments.  In addition, there are ethical
implications involved in utilizing cultured embryos as a
significant source of stem cells.
Therefore, in 2001, my lab investigated the
quality of stem cells isolated from human brain tissue
following death, and in doing so, demonstrated the
potential of postmortem brain tissue to be induced to
achieve a neuronal fate10.  Specifically, we looked at
the difference in quality of neonatal (11-week old
postmortem male) and adult (27-year-old postmortem
male) brain tissue, observing a significantly higher
proliferation capacity yielded by tissues from the young
individuals.  This is not surprising considering the
eventual termination or retardation of cell division that
occurs in conjunction with senisence, or aging of the
cell.  Hence, neonatal postmortem brain tissue may
provide a more quality source of stem cells.
Although intrinsic differences in growth
potential and/or lineage potential may affect the utility of
cell transplantation for therapeutic applications, the
potential use of post-mortem cells for therapy bypasses
some of the ethical complications associated with using
adult-derived and fetal progenitor cells, and should
therefore be seriously considered.
Retrieval of a Method of Isolation Proves Crucial
Considering that there are sources of proliferating stem
cells in the spinal cord and specific regions of the brain,
the development of successful and effective methods
for the isolation of these cells was crucial.  In 2000, my
lab introduced a method for the direct isolation of
human neural stem cells from fresh CNS tissues,
through the identification of cell surface markers and
fluorescence-activated cell sorting (FACS)11.  The
prospective isolation of human CNS stem cells provides
the opportunity to directly delineate lineages derived
from cells at particular stages of development.
The fetal brain stem cells isolated in this
study alone, using the new FACS technique,
demonstrated self-renewal capacity and potent
proliferation, migration, and differentiation into neurons
and glia following engraftment into mouse brains11.  The
ability of this method to detect distinct subsets of
human fetal brain based on a CNS stem cell protein
profile, allows for specific sources of stem cells with
self-renewal and multilineage differentiation properties
to be isolated and evaluated for potential replacement
or repair of damaged tissue.
Mission 2: Decoding the Regulatory Mechanisms of
the Stem Cell
Contributions to Fate Specification
As can be gathered from just my lab’s progress thus far
in identifying promising pools of proliferating stem cells
in the CNS, most of which have the ability to give rise to
neurons both in vitro and in vivo, reports of new cells
being generated throughout the central nervous system
have been mounting.  These findings have lead to an
emerging view that neural stem cells may be widely
distributed in the adult CNS and that the local
environmental cues may dictate their fate choice
(Figure 1).  It is therefore necessary for us to
investigate the contributions to fate specification of
stem cells made by different cell types and
environmental factors.
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Figure 1. Schematic representation of the potential of stem cells to differentiate
Stem cells (SCs) residing in the embryo, brain, blood, or bone marrow may have many different fates, depending on the
cues they receive from their environment.  Hence, determination of the factors influencing their fate specification should
prove to be very valuable in instructing these stem cells toward specific fates for therapeutic purposes.  Such factors
influencing differentiation may include, but are not limited to growth factors, contributions of different cells types (diffusible
and or membrane-bound factors), and voluntary exercise.
Hence, in a 2002 study, my lab and I set out
to determine which type of cells are necessary to
promote neurogenesis—neurons, astrocytes, or both,
and what factors these cell types contribute to neural
promotion12.  We found that while neurons have a role
in inducingstem cells to become oligodendrocytes,
astrocytes have a role in inducing stem cells to become
neurons.  Specifically, our results suggest that rat
hippocampal astrocytes act ively regulated
neurogenesis of adult rat stem cells by promoting
proliferation and increasing the rate of conversion from
progenitors to neurons through both soluble and
membrane-associated factors.  This suggests that
astrocytes play an active regulatory role by contributing
neurogenerative-promoting cues, rather than the merely
supportive role traditionally assigned to them.
Logically, the next step would be to determine what
these factors contributed by astrocytes are and whether
they can be applied to other tissues in need of
increased neural proliferation.
Long Live the Stem Cell!
While we want to devote significant attention to factors
inducing stem cells to achieve neuronal identity, it is
also essential to determine the factors which allow
these stem cells to be maintained, or in other words to
continue to produce more stem cells.   Failure to gain
this knowledge would render the transplantation of
these cells into target tissues for therapeutic purposes
useless.
In September of this year (2003), my lab and
I demonstrated a dose-dependent increase in the
proliferation of adult hippocampal progenitor cells upon
treatment with Insulin-like Growth Factor-2 (IGF-2),
following pretreatment with the already mentioned
growth factor FGF-213.  Our study demonstrated that a
combination of both of these factors is required for
maximum proliferation of these hippocampal stem cells.
In addition, my colleagues have shown the importance
of another factor, BMP (bone morphogenic protein), on
the continued survival and proliferation of stem cells14.
Mission 3: Rescuing the Injured
Although substantial progress has been made in
identifying sources of stem cells and in determining
some of the factors responsible for promoting their
differentiation to neuronal cell fate, it is necessary to
extend our studies to determine the extent to which this
gained knowledge can be applied to treatment of
neurodegenerative diseases and neuronal damage.
Reviving Dopaminergic Neurons
Parkinson’s disease (PD) is a severe neurological
disease characterized by the progressive loss of
dopaminergic neurons in the substantia nigra (SN),
leading to debilitating motor dysfunction.  Thus far, in
our efforts to identify potential strategies for the
replacement of these degenerated neurons, my lab and
I (2002) have determined that progenitor cells actually
reside in the adult SN15.  We demonstrated that while
these progenitors express a glial identity upon
differentiation in situ, they are able to generate cells
from all three neural lineages (neurons, astrocytes, and
oligodendrocytes) in vitro and in vivo in the rat
hippocampus, following removal from the SN and
exposure to appropriate environmental signals.  This
progenitor population thus has the potential to achieve
a neuronal fate, yet, considering their determined failure
to achieve neuronal identity when grafted back into the
SN, it is evident that factors that exist in the SN inhibit
neuronal differentiation15.
Therapeutic Potential
We have illustrated that the potential for Parkinson’s
treatment exists by way of stem cell therapy, provided
we can identify and suppress the neural inhibitory
mechanisms of the SN and identify the necessary
proneural differentiation signals.
Despite our inability to induce a neuronal fate
of SN-derived stem cells, my colleagues have had
success in achieving such differentiation in rat models
of PD using embryonic sources of stem cells16, and also



















(2002) enriched the neuronal generation of midbrain
neural stem cells, derived from mouse ES cells, through
exposure to a combination of Shh, FGF-8, and Nurr1
signaling factors, and demonstrated the ability of these
cells to functionally integrate into target tissue of the
SN, leading to motor recovery in this rodent
Parkinsonian model16.  Scientists have also been
utilizing fetal stem cells for trasnplantation into human
PD patients for greater than a decade with actual motor
function recovery17.  Despite evident complications, this
approach to therapy for neurodegenerative diseased
provides great promise for the future.
Others in Need of Neuroregeneration
My lab is also interested in other neurodegenerative
diseases affecting CNS structures.  The identification of
progenitor cells in the SN, where degeneration of
neurons leads to PD, and illustration of the ability of
non-native stem cells to differente into neurons in the
SN, has lead us to wonder if progenitor cells exist in
other CNS structures associated with severe
neurodegenerative diseases, and if stem cell therapy
can be utilized in these locations as well. For example,
does the caudate nucleus, associated with PD and
Huntington’s disease, or the cerebellum, associated
with Cerebellar Ataxia, also contain progenitor cells,
and what can be done to induce these cells to
differentiate into neurons?
Huntington’s disease (HD) is a debilitating
motor dysfunction disease characterized by the
degeneration of caudate nucleus neurons, which leads
to uncontrolled and involuntary movement.  In October
of this year (2003), we demonstrated the ability of adult
rat-derived neural progenitor cells to survive and
differentiate when transplanted into the striatum of a
hemiparkinsonian rat18.  Although we used a
parkinsonian model, the dopaminergic neurons in the
caudate nucleus and dentate gyrus that are
degenerated in Parkinson’s disease are also
degenerated in HD.  Thus, the research and findings of
this study are therapeutically applicable to HD.
Although not yet tested, all progenitor cells
derived from the various CNS sources, which I
previously introduced, might also have the potential to
be grafted into live human central nervous system
tissues for therapeutic replacement of degenerated
neurons.  Recall that my lab demonstrated such
potential in our ability to engraft human fetal brain
tissue into the brains of mice10.
This idea of providing the correct signals
required for the differentiation of stem cells to specific
neuronal fates, by supplying the cells with a
proneuronal environment (Figure 1), has shown
success in mouse models of spinal cord injury.  Kim, J
et al. (2003) for one, was able to successfully apply the
known specific signals of
the motoneural differentiation pathway in mouse
spinal cord injury models to initiate axonal growth
across the site of injury, which allowed function of the
injured neurons to be partially regained19.
Hence, the idea that progenitor cells simply
need to be given the appropriate signals in order to
coax them to a specific fate has gained a great deal of
support, making it apparent that we must determine
what these signals and cues are and how to apply
them.
Gene Therapy: Another Potential Tactic
While the external environment of progenitor cells has
been demonstrated to greatly influence the fate of the
cell, the genetic components of the cell must also play a
role. Hence, it is important to determine the extent to
which genetic manipulation can direct cell fate.
Gene products known to aid in neurogenesis or to
inhibit neurodegeneration can actually be applied to
degenerated tissues in order to invoke neural growth,
provided they have an effective mode of transport to the
genome of the targeted cells.  Previously available
methods of gene delivery suffered from major
limitations.  Nonviral methods were inefficient and
transient in their expression of the transgene, and the
available viral vectors also demonstrated limitations
(Figure 2).
Figure 2. Currently available methods of gene delivery and their relative value
Lenti-viral vectors and Adeno-associated viruses have proven to offer the most satisfactory combination of efficacy of
gene transfer, sustained transgene expression, and biosafety.  Therefore, these methods may be the most promising for
in vivo gene delivery.  √√ indicates high efficiency of the method, while √ indicated satisfactory efficiency.
While adenoviral vectors allow highly efficient
delivery of the transgene in vivo, its expression is
transient or short-lived mostly due to the immune
response against the transduced cell20.  Vectors
derived from oncoretroviruses are able to integrate the
transgene in the genome of the target cells and without
transferring any viral gene, yet the cells they transduce
die shortly after infection with the transgene20.  In
addition, transcription of the transgene is often shut off
in the transduced cells20.   For a vector to be acceptable
for gene therapy, it must offer a satisfactory
combination of efficient gene transfer to specific targets,














√ √ √√ √√
Non-toxic (biosafety) √√  √ √√ √√
  Gene Therapy Vectors used in the Central Nervous System
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sustained expression of the transgene, and biosafety,
by not inducing cell death (Figure 2)20.
New and Improved Viral Vectors to the Rescue
Tools capable of delivering therapeutic gene products
safely, efficiently, and in sufficient concentration to
affected neurons had to first be developed in order to
successfully deliver gene products known to aid in
neurogenesis or in preventing neurodegeneration in
specific regions of the CNS (growth factors).  We have
succeeded in developing vectors that will allow
therapeutic gene products to be delivered to specifically
targeted, deficient host cells in vivo, without killing the
cells in the process (Figure 2).
In 1996, my lab and I developed a lentiviral
vector (HIV-based vector) capable of efficiently
transferring, integrating, and sustaining long-term
expression of a transgene, β-galactosidase, injected
into adult rat brains20.  The ability of the lentiviral vector
to sustain long-term expression of the transgene is due
to its advantage of integrating into the genome of non-
dividing cells.  This study thus demonstrated the
potential for sustained delivery of a therapeutic gene
product, and hence may permit reversal of the genetic
causes of several innate and acquired diseases in a
wide variety of somatic tissues.
The promise of using the lentiviral vector was
made apparent by Mazarakis, N.D. et al. (2001), who
demonstrated the ability of a delivered rabies viral-
based vector to transduce regions distal from but
projecting to the injection site through retrograde axonal
transport21.  Delivery of the gene marker-containing
vector the rat striatum led to the transduction of
neurons expressing the marker to distal regions,
including neurons of the SN, globus pallidus, and
cerebral peduncle.  In addition to the efficient transfer,
the delivered gene product also exhibited long-term
expression, thus opening up the possibility for the
treatment of incurable human neurodegenerative
diseases such as Alzheimer’s, Parkinson’s, and
motoneuron diseases.
Parkinson’s Disease and Amyotropic Lateral
Sclerosis
Kordower, JH. et al. (2000) actually demonstrated the
utility of the lentiviral approach in the delivery of glial
derived neurotrophic factor (GDNF) to prevent the
degeneration of nigrostriatal neurons in primate models
of PD22.  These effects were non-toxic and long lasting,
and the primates demonstrated potent reversal of
structural and functional effects of dopamine
insufficiency upon delivery of GDNF into the striatum
and SN.
In August of this year (2003), we did a similar
experiment to that of Kordower et al. in an attempt to
reverse the effects of another neurodegenerative
disease, Amyotropic Lateral Sclerosis (ALS)23.
However, we compared the effects of two growth
factors, GDNF, used in Kordower’s study, and IGF-1,
and employed an alternative viral vector, the adeno-
associated virus (AAV).  This virus shows the ability to
efficiently transport gene products from the sight of
injection (muscle) to targeted motor neurons of the
spinal cord by transporting the virus from presynaptic
terminals of projecting neurons through the entire
length of the axon.  The product then enters the
projecting cell nucleus, providing sustained gene
delivery.  The delivery of IGF-1 in our study prolonged
life and delayed progression of the disease in mutant
mice to a greater degree than GDNF.  In addition, we
showed that the effects of IGF-1 delivered by lentivirus
are significantly reduced when compared to the effects
of IGF-1 delivered by AAV.
What about Alzheimer’s disease?
Alzheimer’s disease (AD) is another neurodegenerative
diesease associated with the breakdown of nervous
tissue in the brain, which gives rise to dementia in the
patient.   Abnormal production and accumulation of Aβ
protein is currently being investigated as one of the
central mechanisms leading to (AD).  Hence, in March
of this year (2003), we looked at the ability to deliver
nephrilysin, a human cell-surface associated peptidase
implicated to be a major extracellular Amyloid-β (Aβ)
degrading enzyme in the brain, into transgenic mouse
models of amyloidosis, using a lentiviral vector24.  This
study demonstrated the inhibitory effect of nephrilysin
on Aβ  deposits in mice, either through increased
degradation or reduced growth of already existing
plaques, and its ability to reduce neurodegeneration.
Our study therefore supports a role for nephrilysin in the
regulation of amyloid deposition, and highlights the
potential use of gene therapy approaches for the
treatment of Alzheimer’s disease.
Conclusion
Considering that this field of study has both an
enormous potential impact on human health and quality
of life, and that it is an exploding area in new research
discovery, continued research efforts made on my part
and on the part of my fellow colleagues is inevitable.
We are currently striving to further expand our scope of
knowledge concerning the ability to manipulate the fate
of these self-renewing progenitor cells and to apply the
knowledge we gain to the treatment of central nervous
system damage.
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